Boston Scientific Q2 Earnings Call Highlights

{
  "signal_id": "45178f8e-2d31-915d-2c89-ad50a050e214",
  "signal_type": "news",
  "signal_subtype": "has_earnings",
  "detected_at": "2026-07-29T20:03:58+00:00",
  "company": {
    "name": "Boston Scientific",
    "domain": "bostonscientific.com"
  },
  "data": {
    "url": "https://www.tradingview.com/news/marketbeat:12a120378094b:0-boston-scientific-q2-earnings-call-highlights/",
    "title": "Boston Scientific Q2 Earnings Call Highlights - TradingView",
    "excerpt": "Boston Scientific BSX reported second-quarter 2026 revenue growth at the high end of its guidance range and adjusted earnings per share above expectations, but lowered its full-year outlook as it faces slowing demand in its WATCHMAN left atrial appendage closure business and increased competitive pressure in U.S. electrophysiology. Chief Executive Officer Mike Mahoney said organic sales rose 7% in the second quarter, while adjusted earnings per share increased 15% to $0.86. The company had guided for 5% to 7% organic revenue growth and adjusted EPS of $0.82 to $0.84. Mahoney said the EPS outperformance was primarily driven by favorable tax results. Boston Scientific now expects full-year organic revenue growth of 5% to 6%, compared with its prior outlook, and adjusted EPS of $3.28 to $3.32, representing growth of 7% to 8%. For the third quarter, the company projected organic revenue growth of 3% to 5% and adjusted EPS of $0.80 to $0.82. WATCHMAN and EP Drive Outlook Reduction Mahoney said the revised outlook was concentrated in two businesses that had previously been major growth drivers: WATCHMAN and electrophysiology, or EP. WATCHMAN sales grew 4% in the second quarter, including 18% international growth and 3% growth in the U.S. The company estimated that roughly one-third of U.S. WATCHMAN procedures are now performed concomitantly with other procedures. Concomitant...",
    "summary": "Boston Scientific reported adjusted earnings per share of $0.86 for the second quarter of 2026, a 15% increase.",
    "planning": false,
    "image_url": "https://s.tradingview.com/static/images/illustrations/news-story.jpg",
    "confidence": 0.9,
    "published_at": "2026-07-29T20:03:58Z",
    "article_sentence": "Chief Executive Officer Mike Mahoney said organic sales rose 7% in the second quarter, while adjusted earnings per share increased 15% to $0.86."
  }
}

curl https://signals.autobound.ai/v1/signals/45178f8e-2d31-915d-2c89-ad50a050e214 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"bostonscientific.com","limit":20}'